文献速递细菌感染、耐药与抗菌药物

抗菌药物管理是否具有成本效益?一项叙述性综述

Is antimicrobial stewardship cost-effective? A narrative review of the evidence.
PubMed 文献 · Clin Microbiol Infect · 2017-06-20

该叙述性综述检索PubMed 2000年1月至2017年3月发表的评估抗菌药物管理(AMS)干预成本效果、成本效用或成本效益的人类研究,未限定研究场景。综述指出说服性和结构性AMS干预可能为医院场景带来卫生经济学获益,但AMS的成本效果证据严重有限,尤其在社区场景,尚不足以支持投资决策。

要点

  • 说服性和结构性AMS干预可能为医院场景带来卫生经济学获益。
  • AMS成本效果证据严重有限,社区场景尤为不足。
  • 现有证据不足以支持决策者评估AMS项目是否提供足够获益。

核心结论

  • AMS的成本效果证据虽在增加,但仍不足以支持投资决策。
  • 说服性和结构性AMS干预可能为医院场景带来卫生经济学获益。
  • 需开展稳健的卫生经济学研究以提升成本效果结果的通用性和可用性。

研究设计与样本

  • 叙述性综述,检索PubMed 2000年1月至2017年3月发表的评估AMS干预成本效果、成本效用或成本效益的人类研究,未限定研究场景。
  • 同时检索已获取综述的参考文献列表以补充文献。

主要发现

  • 研究提示说服性和结构性AMS干预可能为医院场景提供卫生经济学获益。
  • 总体而言,AMS的成本效果证据严重有限,尤其在社区场景。

临床怎么用

  • 决策者目前缺乏必要证据评估AMS项目是否提供足够获益。
  • 未来研究需讨论合适的卫生经济学方法学选择。

局限性

  • AMS成本效果证据严重有限,尤其社区场景。
  • 现有证据基础不足以支持投资决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: This narrative review aimed to collate recent evidence on the cost-effectiveness and cost-benefit of antimicrobial stewardship (AMS) programmes, to address the question 'is AMS cost-effective?', while providing resources and guidance for future research in this area. SOURCES: PubMed was searched for studies assessing the cost-effectiveness, cost-utility or cost-benefit of AMS interventions in humans, published from January 2000 to March 2017, with no setting inclusion/exclusion criteria specified. Reference lists of retrieved reviews were searched for additional articles. CONTENT: Recent evidence on the cost-effectiveness and cost-benefit of AMS is described, studies suggest persuasive and structural AMS interventions may provide health economic benefits to the hospital setting. However, overall, cost-effectiveness evidence for AMS is severely limited, especially for the community setting. Recommendations for future research in this area are therefore provided, including discussion of appropriate health economic methodological choice. IMPLICATIONS: Health systems have a finite and decreasing resource, decision makers currently do not have necessary evidence to assess whether AMS programmes provide sufficient benefits. Although the evidence-base of the cost-effectiveness of AMS is increasing, it remains inadequate for investment decision-making. Robust health economics research needs to be completed to enhance the generalizability and usability of cost-effectiveness results.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Naylor NR, Zhu N, Hulscher M, et al. Is antimicrobial stewardship cost-effective? A narrative review of the evidence. Clin Microbiol Infect. 2017. PMID: 28642146. doi:10.1016/j.cmi.2017.06.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。